Indivior (NASDAQ:INDV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Indivior (NASDAQ:INDV - Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

Separately, Piper Sandler decreased their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $15.00.

Indivior Price Performance

NASDAQ INDV traded down $0.03 during trading on Friday, hitting $13.92. 757,905 shares of the company's stock traded hands, compared to its average volume of 1,110,443. The stock has a fifty day moving average of $11.86 and a two-hundred day moving average of $11.07. Indivior has a 12-month low of $7.33 and a 12-month high of $16.69. The firm has a market cap of $1.93 billion, a P/E ratio of -44.90 and a beta of 0.66.

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to analysts' expectations of $240.13 million. Indivior had a negative return on equity of 97.29% and a negative net margin of 4.02%. As a group, analysts expect that Indivior will post 1.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Indivior

Several institutional investors and hedge funds have recently bought and sold shares of INDV. Deerfield Management Company L.P. Series C raised its holdings in shares of Indivior by 74.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after acquiring an additional 3,790,518 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company's stock valued at $79,757,000 after purchasing an additional 1,299,425 shares during the period. Vanguard Group Inc. raised its holdings in Indivior by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 4,631,221 shares of the company's stock worth $43,765,000 after purchasing an additional 71,539 shares in the last quarter. Newtyn Management LLC lifted its position in shares of Indivior by 17.4% in the 1st quarter. Newtyn Management LLC now owns 1,650,938 shares of the company's stock worth $15,733,000 after purchasing an additional 244,407 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Indivior by 36.9% during the 4th quarter. Millennium Management LLC now owns 1,233,006 shares of the company's stock valued at $15,326,000 after purchasing an additional 332,180 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.